TESAMORELIN

290.00 AED — In stock

Tesamorelin is a synthetic growth hormone‑releasing hormone (GHRH) analog developed to stimulate endogenous growth hormone (GH) secretion from the pituitary gland. Clinically approved for the reduction of visceral adipose tissue (VAT) in patients with HIV‑associated lipodystrophy, Tesamorelin is also used in wellness and longevity research for fat loss, metabolic regulation, and body‑composition support. By enhancing natural GH release, Tesamorelin helps target abdominal fat, improve lipid metabolism, and support overall metabolic balance, making it one of the most studied peptides for targeted fat reduction in human models. Key Features 🧪 cGMP manufactured in an FDA‑registered facility✅ ≥98% purity confirmed by HPLC analysis📄 Batch‑specific Certificates of Analysis (COAs) included💉 Sterile, lyophilized vials for research use only Human‑Relevant Research Applications 🔥 Visceral fat reduction in humansIn clinical randomized trials, Tesamorelin significantly reduces visceral adipose tissue (VAT) — the metabolically active belly fat — compared with placebo over 6 months in adults with central fat accumulation. 🔗 https://pubmed.ncbi.nlm.nih.gov/20101189/ 📉 Improved body composition & metabolic markersMeta‑analyses show Tesamorelin reduces VAT and trunk fat, improves lipid profiles, and increases lean body mass without adverse impacts on glucose homeostasis in human subjects. 🔗 https://pubmed.ncbi.nlm.nih.gov/41545261/ 💪 Sustained effects with continued treatmentPhase III clinical data demonstrate that VAT reductions are maintained with ongoing Tesamorelin use up to 52 weeks, with associated improvements in triglycerides and waist circumference. 🔗 https://pubmed.ncbi.nlm.nih.gov/20554713/ Mechanism Summary Stimulates growth hormone‑releasing hormone (GHRH) receptors in the anterior pituitary Promotes pulsatile secretion of endogenous growth hormone Increases IGF‑1 levels, which mediate fat metabolism and tissue maintenance Targets visceral adiposity more than subcutaneous fat via GH‑driven lipolytic signaling Reconstitution & Handling Guidance 1️⃣ Use sterile bacteriostatic water (0.9% benzyl alcohol)2️⃣ Add 3 ml of bacteriostatic water for peptide reconstitution3️⃣ Gently swirl — do not vortex — until fully dissolved4️⃣ Store reconstituted vial at 4 °C–10 °C for 2–3 months5️⃣ Unreconstituted vials remain stable until expiry at 4 °C–10 °C Frequently Asked Research Questions How does Tesamorelin differ from direct GH injection?Tesamorelin stimulates natural GH secretion by activating GHRH pathways, preserving physiological pulsatility and feedback mechanisms, unlike continuous GH dosing. Does Tesamorelin influence subcutaneous fat?Clinical studies show the most pronounced effects are on visceral adipose tissue, with minimal change in subcutaneous fat — reflecting targeted fat‑metabolism pathways. Legal & Research Disclaimer This material is supplied exclusively for laboratory research use. It is not intended for diagnostic, therapeutic, cosmetic, human, or veterinary applications. The purchaser assumes all responsibility for compliance with applicable local, state, and federal regulations governing research compounds.

More All Products

What is TESAMORELIN?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It contains all 44 amino acids of natural human GHRH, with a trans-3-hexenoic acid group added at the start. This change helps protect it from breakdown in the body.

Tesamorelin acts on GHRH receptors in the pituitary gland. This prompts the body to release its own growth hormone in pulses, rather than supplying growth hormone directly. Growth hormone then raises levels of IGF-1 and is involved in fat metabolism. It is given by injection under the skin.

Also known as: Egrifta, TH9507, Tesamorelin acetate, GHRH analogue

What are peptides?

What the research covers

Tesamorelin has been studied in large randomised, placebo-controlled human trials. Phase 3 trials in people with HIV and excess abdominal fat reported reductions in visceral fat measured by CT scan over 26 weeks, compared with placebo. It has also been studied in smaller trials for liver fat and cognitive ageing. Reported side effects included joint pain, injection site reactions and changes in blood sugar. Tesamorelin is approved by the US FDA as Egrifta to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for general weight loss.

References

Formats available

Pen

Pre-filled pen prepared by a licensed compounding pharmacy for subcutaneous use.

Cartridge

Pre-filled cartridge for use with a compatible reusable pen device.

Vial (injectable)

Vial for subcutaneous injection, prepared by a licensed compounding pharmacy.

Storage and handling

Storage: Keep pens and cartridges refrigerated at 2-8C and protect them from light. Lyophilised vials should be refrigerated at 2-8C after reconstitution, kept away from light and never frozen. Follow the storage instructions on your pharmacy label.

Peptide Calculator

Specification

Property	Value
Type	Synthetic GHRH analogue (N-terminal trans-3-hexenoyl modification)
Peptide length	44 amino acids
Molecular weight	approx. 5136 g/mol
Formats	Pen, Cartridge, Vial (injectable)

Frequently asked questions

Is tesamorelin approved?

Yes, for one use. The US FDA approved it as Egrifta to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Other uses are off-label and your GP will discuss this with you.

How is it different from sermorelin or CJC-1295?

All three act on GHRH receptors. Sermorelin is a shorter 29-amino-acid fragment. Tesamorelin is the full 44-amino-acid sequence with a stabilising modification, and it is the one with large phase 3 trial data.

What formats are available and how are they stored?

It is available as a pen, cartridge or vial. Keep pens and cartridges in the fridge, and refrigerate vials after reconstitution, away from light. Follow the storage instructions on your pharmacy label.

Are there side effects?

Side effects can occur. Your GP will review your health, medication and, where relevant, blood results before prescribing, and you should report anything unexpected.

How much should I take?

Your dose is set by our licensed GP following a consultation, and printed on your pharmacy label.